해외뉴스
(해외) 합성생물학 뉴스
해외뉴스
총 게시물 1023건
| 943 | 기술 |
N새글
Catalan researchers create "new switches" to control anything with AI
"We have taken a very important step towards understanding the language of DNA." With this statement, Lars Velten, a researcher at the Center for Genomic Regulation (CRG), tried to quantify the extent to which the results of the study his team published this Thursday in the journal CellThe research group from the CRG and EMBL-Barcelona has succeeded in creating an artificial intelligence (AI) tool capable of designing regulatory DNA sequences never seen in nature. "We can say that we have created new switches [enhancers] that until now did not exist in the mammalian genome and that in the future could be used to control whether a gene is turned on or not in a specific cell," explains Velten, lead author of the research.
|
| 942 | 기술 |
N새글
The first genetic editing in spiders with CRISPR‐Cas yields colorful silk
The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 gene-editing tool to spiders. Following the genetic modification, the spiders produced red fluorescent silk. Spider silk is one of the most fascinating fibers in the field of materials science. In particular, its dragline thread is extremely tear-resistant, while also being elastic, lightweight and biodegradable. If scientists succeed in influencing spider silk production in vivo—in a living animal—and thereby gain insights into the structure of the dragline thread, it could pave the way for the development of new silk functionalities for a wide range of applications.
|
| 941 | 기술 |
N새글
AI-designed DNA controls genes in healthy mammalian cells for first time
A study published today in the journal Cell marks the first reported instance of generative AI designing synthetic molecules that can successfully control gene expression in healthy mammalian cells. Researchers at the Centre for Genomic Regulation (CRG) created an AI tool which dreams up DNA regulatory sequences not seen before in nature. The model can be told to create synthetic fragments of DNA with custom criteria, for example: 'switch this gene on in stem cells which will turn into red-blood-cells but not platelets.' The model then predicts which combination of DNA letters (A, T, C, G) are needed for the gene expression patterns required in specific types of cells. Researchers can then chemically synthesise the roughly 250-letter DNA fragments and add them to a virus for delivery into cells.
|
| 940 | 기술 |
N새글
AI model provides clues about how a virus may evolve and the immune response it could provoke
The new model, described May 8 in the journal Immunity, uses evolutionary, biological, and structural information about a virus to predict and design surface proteins likely to occur as the pathogen mutates. The researchers successfully applied EVE-Vax to SARS-CoV-2, designing viral proteins that elicited similar immune responses as the actual proteins that evolved during the COVID-19 pandemic. The research suggests that the model provides valuable information about the future evolution of a virus and can be used to create panels of "designer" proteins to evaluate the future protection of vaccines. The researchers hope that the model will eventually help scientists develop better vaccines to combat viral outbreaks and pandemics caused by rapidly mutating viruses.
|
| 939 | 기술 |
N새글
In vivo 3D printing using sound holds promise for precise drug delivery, wound healing and more
A team of scientists led by Caltech has taken a significant step toward that ultimate goal, having developed a method for 3D-printing polymers at specific locations deep within living animals. The technique relies on sound for localization and has already been used to print polymer capsules for selective drug delivery as well as glue-like polymers to seal internal wounds. They came up with a novel approach: Combine ultrasound with low-temperature–sensitive liposomes. Such liposomes, spherical cell-like vesicles with protective fat layers, are often used for drug delivery.
|
| 938 | 산업 |
N새글
CRISPR’s Casgevy on the Rise With More Gene Therapy Proof of Concept To Come in 2025
CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy Casgevy. While Vertex handles the market, CRISPR has been focused on its clinical program. The outlook for CRISPR Therapeutics’ approved gene therapy Casgevy is starting to look up, with more treatment centers added over the past quarter. The positive trend comes just as the gene editing biotech reported that its cholesterol-lowering gene therapy dropped lipoprotein and triglycerides in a Phase I trial, showcasing the potential of gene therapy if the space can overcome its commercial hurdles. CRISPR’s partner Vertex reported earlier this week that more than 65 treatment centers have been activated for Casgevy, which is approved for sickle cell disease and beta-thalassemia. The revelation provided a glimmer of hope for the gene therapy space, which has been battered by bad news.
|
| 937 | 정책 |
N새글
“The future of plant science in England is bright” – researchers welcome the passing of Precision Breeding legislation for plants
Following the news that Parliament has passed the secondary legislation to implement the Genetic Technology (Precision Breeding) Act for plants in England, we welcome the benefits this offers, and the increased opportunities for plant and microbial science to improve the health of plants, people and the planet. “The passing of this forward-thinking legislation means that this science will be able to benefit the health of people, plants, and the planet. The use of precision breeding technologies in research will expand our understanding of plant genetics and strengthen the entire agricultural science ecosystem, reinforcing the country’s leadership in agricultural innovation.”
|
| 936 | 기술 |
N새글
Ribbon Bio Launches MiroSynth™ DNA Molecules to Unlock a New Era of Complex Synthetic DNA
First Commercial Offering Delivers Complex, Long, and Highly Accurate DNA to Power Transformative Scientific Breakthroughs. VIENNA--(BUSINESS WIRE)--Ribbon Bio GmbH, the DNA synthesis company, today announced the launch of MiroSynth™ DNA, its first commercial product designed to meet the growing demand for complex and highly-accurate synthetic DNA molecules. The product launch coincides with the Global Synthetic Biology Conference in San Jose, California, taking place May 5–8, 2025. MiroSynth™ DNA is built on Ribbon’s proprietary algorithm-driven technology and precision enzymatic assembly process, delivering exceptional accuracy and performance for applications initially in biopharma, life sciences and academic research. Customers and partners across the US, EU, UK, and Australia can now access MiroSynth™ DNA to accelerate their most ambitious scientific work.
|
| 935 | 정책 |
N새글
DBT and BIRAC Invite Bio-AI Proposals to Set up Mulankur Hubs
The Union Cabinet approved the BioE3 (Biotechnology for Economy, Environment, & Employment) Policy, in August 2024, for ‘Fostering High-Performance Biomanufacturing’ across the country. Subsequently, The Union Cabinet, chaired by the Prime Minister Narendra Modi, approved continuation of the two umbrella schemes of Department of Biotechnology (DBT), merged as one scheme-‘Biotechnology Research Innovation and Entrepreneurship Development (Bio- RIDE)’ with a new component namely Biomanufacturing and Biofoundry. With in the ambit of “High -Performance Biomanufacturing”, establishment of Bio-AI hubs for building of data driven and cutting edge paradigms in the areas of Health, Agriculture and Environment.
|
| 934 | 기술 |
N새글
Harnessing generative AI to expand the mitochondrial targeting toolkit
The mitochondrion plays critical roles in cellular function, making it a prime organelle to target for fundamental studies, metabolic engineering, and disease therapies. With only a limited number of existing mitochondrial targeting sequences, a new study from the Carl R. Woese Institute for Genomic Biology demonstrates the utility of generative artificial intelligence for designing new ones. Using an unsupervised deep learning framework called Variational Autoencoder, the research team identified key features of MTSs, including being positively charged and amphiphilic and tending to form an α-helix. They then designed a million AI-generated MTSs and experimentally tested the mitochondrial targeting abilities of 41 of them. Using confocal microscopy for the validation studies, they achieved a 50% to 100% success rate in yeast, plant cells, and mammalian cells.
|